Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the ...

Noom is the latest digital health company to jump into the off-label weight loss drug market to make medications more ...

Following a monthslong battle over CEO Anne Wojcicki’s plans to take 23andMe private, all seven independent members of its ...

Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has ... drug is administered orally – which makes it easier to take than Novo Nordisk’s Wegovy and Eli ...

However, after its phase 1 success with TERN-601, it will raise more money by taking advantage of its soaring stock price and ...

Company earnings reported early in the quarter showed growth remained strong, with improved manufacturing volumes and steady ...

Company is investing $2.8bn in two Irish plants to produce its in-demand weight loss drugs and a new Alzheimer’s therapy ...

A first-of-its-kind analysis conducted as part of an investigation by journalists in eight countries found that some of the ...

However, the analysts said: “Given our own forecast that CPI inflation will rise back to 2.9pc by January next year (perhaps ...

Viking Therapeutics Inc. (NASDAQ: VKTX), a clinical-stage biotechnology company with a market cap approaching $7 billion, is ...

As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...